Nevirapine

ARV U.S. Brand Name

Viramune, Viramune XR

ARV Abbreviation(s)

NVP

U.S. FDA Label

Nevirapine Labeling (Package Insert)

ARV Class

Nonnucleoside reverse transcriptase inhibitors

First U.S. Approval

June 21, 1996

U.S. Manufacturer

Boehringer Ingelheim

Formulations

Strength	Formulation	Image	Description	Boosted
200 mg	Immediate-release (IR) Tablet	X	oval white pill with 54\|193 imprint	No
400 mg	Extended-release (XR) Tablet	X	oval yellow tablet with V04 imprint	No
50-mg/5 mL	Oral Suspension	X	white bottle with viramune oral suspension 50-mg/5 mL on label	No
100 mg	Extended-release (XR) Tablet	X	round yellow tablet with V01 imprint (generic)	No
				No

Generic Available?

Yes

Other Reference Links

Clinical Info HIV Drug Database

National HIV Curriculum

Assistance Programs

BI Cares

Displaying 1 - 78 of 78

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Lenacapavir Nevirapine	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Potential loss of antiviral efficacy				Use alternative agents
Darunavir NVP 910	Green: Administer standard doses	Administer standard doses		Cmax increase 40%, AUC increase 24%, Cmin increase 2%	200 mg BID	Cmax increase 18%, AUC increase 27%, Cmin increase 47%
Atazanavir NVP 824	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition		Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	Contraindicated. Use alternative agents.
Nevirapine TDF 643			Potential early virologic failure	Not studied			Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment naive patients
Nevirapine CsA 642	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Nevirapine Clarithromycin 641	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	Decreased clarithromycin effects but increased metabolite concentrations		500 mg BID	Clarithromycin AUC decreased 31%; Cmax decreased 23%; Cmin decreased 56%; 14-hydroxy clarithromycin AUC increased 42%, Cmax increased 47%	Consider using alternative agents such as Azithromycin
Nevirapine MMF, MPA 640	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination		No significant change	500 mg BID x 8 weeks	Not studied	Use alternative agents
Nevirapine DRV 639	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased Nevirapine effects, increased risk of hepatotoxcity	AUC increased 110%			Use alternative agents
Nevirapine SQV 638	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased saquinavir effects	Not studied	600 mg (hard gel caps) TID	Saquinavir AUC decreased 24%; Cmax decreased 28%	Use alternative agents
Nevirapine Diltiazem 637	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased dilitazem efficacy				If coadministring, titrate dilitazem based on clinical response
Nevirapine CBZ 636	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased anticonvulsant and NVP concentration				If coadministring, monitor anticonvulsant and NVP concentration
Nevirapine Caffeine / Ergotamine 635	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Ergotamine levels may be decreased	No significant change		Not studied (may decrease ergot levels)	If coadministering, monitor for ergot efficacy
Nevirapine Warfarin 634	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased warfarin effects (eg, altered INR, increased risk of clotting)				If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Nevirapine Bosentan 633	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased etravirine effects; potential decreased bosentran effects				If coadministring, monitor bosentran efficacy and virologic response
Nevirapine Ticagrelor 632	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased ticagrelor levels				Avoid combination and use alternative agents
Nevirapine Itraconazole 631	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects and possible NVP concentrati			Itraconazole AUC decreased 61%	Avoid combination and use alternative agents
Nevirapine Tamsulosin 630	Orange: Minimal data to guide interaction	Adjust dosing to avoid decreased levels of tamsulosin	Decreased tamsulosin effects				If coadministring, monitor for theraptutic effectiveness of tamsulosin after 2-4 weeks. Increase dose to 0.8mg daily for patients who fail to respond to 0.4 mg dose.
Nevirapine SOF/VEL 629	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir and voxilaprevir	Potential loss of anti-HCV efficacy			Not studied (may decrease velpatasvir and voxilaprevirlevels)	Contraindicated. Use alternative agents.
Nevirapine SOF/VEL 628	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir	Potential loss of anti-HCV efficacy			Not studied (may decrease velpatasvir levels)	Contraindicated. Use alternative agents.
Nevirapine Cariprazine 627	Red: Avoid combination	Do not coadminister: potientially reduced levels of cariprazine	Potential decreased cariprazine effects				Contraindicated. Use alternative agents.
Nevirapine Pimavanserin 626	Red: Avoid combination	Do not coadminister: Reduced levels of pimavanserin	Decreased pimavanserin levels				Avoid combination and use alternative agents
Nevirapine RIF 625	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects		600 mg daily		Use alternative agents
Nevirapine RIF 624	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects		450 mg if < 55 kg and 600 mg if > 55 kg x 7 days		Use alternative agents
Nevirapine RIF 623	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects			Not studied	Use alternative agents
Nevirapine RIF 622	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects		600 mg daily	No significant change	Use alternative agents
Nevirapine RPT 621	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects			Cmin decreased 27%	Contraindicated. Use alternative agents.
Nevirapine Lumateperone 620	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Decreased Lumateperon levels				Avoid combination and use alternative agents
Nevirapine LNG 619	Red: Avoid combination	Do not coadminister: Reduced levels of levonorgestrel				Levonorgestrel AUC increased 35%
Nevirapine Ketoconazole 618	Red: Avoid combination	Do not coadminister: Reduced levels of ketoconazole	Decreased ketoconazole effects		400 mg daily	Ketoconazole AUC decreased 72%; Cmax decreased 44%	Use alternative agents
Nevirapine ETR 617	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Decreased etravirine and nevirapine effects	levels): increased 15-30%		Etravirine AUC decreased 55%	Use alternative agents
Nevirapine Ethinyl estradiol / Norethindrone acetate 616	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol and progesterone	Possible contraceptive failure		Ethinyl estradiol 0.035 mg / Norethindrone 1 mg daily x 30 days	Ethinyl estradiol: AUC decreased 23%; half-life: decreased 44%; Norethindrone: AUC decreased 18%; half-life: decreased 15%	Use alternative contraceptive method
Nevirapine Ethinyl estradiol / Norethindrone acetate 615	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol and progesterone	Possible contraceptive failure		Ethinyl estradiol 0.035 mg / Norethindrone 1 mg x 1 dose	Ethinyl estradiol AUC decreased 19%; Cmax no significant change. Norethindrone AUC decreased 18%	Use alternative contraceptive method
Nevirapine ATV 614	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Decreased atazanavir effects	Not studied	400 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 19%; Cmax no significant change; Cmin decreased 59%	Use alternative agents
Nevirapine ATV 613	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Decreased atazanavir effects	No significant change	300 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 42%; Cmax decreased 28%; Cmin decreased 72%	Use alternative agents
Nevirapine Artemether / Lumefantrine 612	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine			artemether / lumefantrine 80 mg / 480 mg x 6 doses	Lumefantrine AUC increased 56%; Cmax increased 24%; half-life: no significant change; clearance: decreased 36%	Use alternative agents
Nevirapine Artemether / Lumefantrine 611	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine	Potentially increased treatment failure		artemether / lumefantrine 80 / 480 mg	Lumefantrine AUC decreased 21%; Cmax decreased 30%	Use alternative agents
Nevirapine Artemether / Lumefantrine 610	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine	Potentially increased treatment failure		artemether / lumefantrine 80 / 480 mg	Artemether AUC decreased 72%; Cmax decreased 61%; Lumefantrine AUC decreased 21%; Cmax decreased 30%	Use alternative agents
Nevirapine SOF/VEL 609	Red: Avoid combination	Do not coadminister: Potential for reduced levels of sofosbuvir	Potential loss of anti-HCV efficacy	Nevirapine AUC decreased 79%; Cmax decreased 20%; Cmin decreased 60%; half-life: decreased 66%		Potential decrease in sofosbuvir and velpatasvir levels).	Use alternative agents
Nevirapine St. John's Wort (Hypericum perforatum) 608	Red: Avoid combination	Do not coadminister: Potential for reduced levels of NVP	loss of virologic response			Not studied	Contraindicated. Use alternative agents
Nevirapine Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide 607	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Potentially decreased or increased elvitegravir, cobicistat and / or nevirapine effects	Not studied		Not studied	Use alternative agents
Nevirapine EBR/GZR 606	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Decreased elbasvir, grazoprevir levels expected	Nevirapine AUC decreased 31%; Cmax decreased 36%; Cmin decreased 21%		Not studied (may decrease grazprevir levels)	Contraindicated. Use alternative agents.
Nevirapine EBR/GZR 605	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Potentially decreased elbasvir, grazoprevir levels expected			Not studied (may decrease grazprevir levels)	Avoid combination. Use alternative agents
Nevirapine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 604	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dasabuvir, ombitasvir, and paritaprevir	Potential decrease in HCV agent efficacy	Nevirapine AUC decreased 27% (at week 4); Nevirapine AUC no significant change (at week 10)Nevirapine AUC with rifampicin approximates nevirapine baseline without rifampicin at week 10.		Not studied (may decrease paritaprevir levels)	Use alternative agents
Nevirapine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 603	Red: Avoid combination	Do not coadminister: Potential for reduced levels of anti-HCV agents	Potential decrease in anti-HCV efficacy			Not studied (may decrease paritaprevir levels)	Use alternative agents
Nevirapine AZT, ZDV 602	Green: Administer standard doses	Administer standard doses		No significant change	100-200 mg TID
Nevirapine Daclatasvir 601	Green: Administer standard doses	Administer standard doses		Cmin decreased 16%		Rifabutin AUC increased 17%, metabolite AUC increased 24%
Nevirapine Medroxyprogesterone acetate 600	Green: Administer standard doses	Administer standard doses			150 mg	Progesterone levels): no significant change
Nevirapine Paclitaxel 599	Green: Administer standard doses	Administer standard doses		No significant change	100 mg / square meter infusion over 3 hours	Not studied
Nevirapine DTG 598	Green: Administer standard doses	Administer standard doses		Nevirapine Cmin increased 22%	50 mg daily	Dolutegravir AUC decreased 19%; Cmin decreased 34%
Nevirapine DRV 597	Green: Administer standard doses	Administer standard doses	Potential for increased darunavir effects; Potential for increased nevirapine effects	Nevirapine AUC increased 110%; Cmax increased 115%; Cmin increased 135%; half-live: decreased 52% (data compared to historical controls)	400 mg BID with ritonavir 100 mg BID	Darunavir AUC increased 24%; Cmax increased 40%
Nevirapine RFB 596	Green: Administer standard doses	Administer standard doses	Decreased antiviral efficacy	AUC decreased 31%		AUC increased 26%
Nevirapine RFB 595	Green: Administer standard doses	Administer standard doses	Decreased antiviral efficacy	No significant change in nevirapine Cmin	150 or 300 mg daily	AUC increased 17%, Cmax increased 28% and 25-O-desacetyl-rifabutin AUC increased 24%
Nevirapine MVC 594	Green: Administer standard doses	Administer standard doses		Nevirapine AUC no significant change	300 mg single dose	Maraviroc Cmax increased 54%	Use standard dose maraviroc. If coadministering with nevirapine plus a protease inhibitor, reduce dose of maraviroc to 150 mg BID
Nevirapine RTV 593	Green: Administer standard doses	Administer standard doses		Nevirapine AUC decreased 40%	600 mg BID	No significant change	No dose adjustment necessary
Nevirapine Linagliptin 592	Green: Administer standard doses	Administer standard doses	Possible decrease in antihyperglycemic effects				Monitor glycemic control
Nevirapine Atorvastatin 591	Green: Administer standard doses	Administer standard doses	Decreased lipid effects			Atorvastatin AUC decreased 32%-43%	Monitor for statin efficacy. May need to increase atorvastatin dose
Nevirapine Trazodone 590	Green: Administer standard doses	Administer standard doses	Decreased trazadone effects				Monitor for signs and symptoms of depression and titrate trazadone to effect
Nevirapine Sertraline 589	Green: Administer standard doses	Administer standard doses	Decreased sertaline effects				Monitor for signs and symptoms of depression and titrate sertaline to effect
Nevirapine Escitalopram 588	Green: Administer standard doses	Administer standard doses	Decreased escitalopram effects				Monitor for signs and symptoms of depression and titrate escitalopram to effect
Nevirapine Bupropion 587	Green: Administer standard doses	Administer standard doses	Decreased bupropion effects				Monitor for signs and symptoms of depression and titrate bupropion to effect
Nevirapine Fluconazole 586	Green: Administer standard doses	Administer standard doses	Potential for increased nevirapine effects		200 mg three times weekly		Monitor for nevirapine toxicity
Nevirapine Fluconazole 585	Green: Administer standard doses	Administer standard doses	Increased nevirapine effects		200 mg daily x 40 days	No significant change	Monitor for nevirapine toxicity
Nevirapine Isavuconazole 584	Green: Administer standard doses	Administer standard doses	Possible decreased Isavuconazole levels				monitor for isravucanazole concentrations and anti fungal response
Nevirapine Methadone 583	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, withdrawal)		stable dose: racemic methadone 35-220 mg daily; (R)-methadone 45-115 mg daily	racemic methadone AUC decreased 37%; (R)-methadone AUC decreased 44%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Nevirapine Methadone 582	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, methadone withdrawal; interaction observed one week into therapy	Nevirapine AUC increased 26%; Cmax increased 21%; Cmin increased 35%	Stable methadone maintenance	Methadone AUC decreased 46%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Nevirapine Methadone 581	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, methadone withdrawal)	Nevirapine AUC increased 25%; Cmax increased 17%; Cmin increased 32%	Stable methadone dose	Methadone AUC decreased 51%; Cmax decreased 36%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Nevirapine Methadone 580	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects	Nevirapine AUC decreased 46%; Cmax decreased 42%	stable dose	Not reported	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Nevirapine IDV 579	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of indinavir	Decreased indinavir effects		800 mg Q8H	Indinavir AUC decreased 31%; Cmax decreased 15%, Cmin decreased 44%	Increase indinavir to 1000 mg Q8H
Nevirapine FPV 578	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of fosamprenavir		Not studied	700 mg fosamprenavir BID with 100 mg ritonavir BID	No significant change	Do not use with fosamprenavir alone. Ritonavir boosted fosamprenavir (700 / 100 mg BID) can be considered
Nevirapine FPV 577	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of fosamprenavir	Decreased fosamprenavir effects	Nevirapine AUC decreased 46%; Cmax decreased 42%	1400 mg BID	Fosamprenavir AUC decreased 33%; Cmax decreased 25%; Cmin decreased 35%	Do not use with fosamprenavir alone. Ritonavir boosted fosamprenavir (700 / 100 mg BID) can be considered
Nevirapine Daclatasvir 576	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Potential loss of anti-HCV efficacy	Nevirapine Cmin decreased 16%		Not studied (may decrease daclatasvir levels)	Increase daclatasvir dose to 90 mg daily.
Nevirapine Daclatasvir 575	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Potential loss of anti-HCV efficacy		120 mg daily	AUC increased 37% and Cmin decreased 17%.	Increase daclatasvir dose to 90 mg daily.
Etravirine NVP 553	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine					Avoid combination: :combining two NNRTIs has not been shown beneficial use alternate agents
Efavirenz NVP 502	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz effects	Efavirenz AUC decreased 22%; Cmin decreased 36%	200 mg daily x 2 weeks, then 400 mg daily	No significant change	Monitor and adjust therapy as indicated; may consider increasing efavirenz to 800 mg daily
Doravirine NVP 355	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Do not coadminister. Use alternative agents.
Dolutegravir NVP 121	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dolutegravir	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Maraviroc NVP 56	Green: Administer standard doses	Administer standard doses		Maraviroc AUC no change; Cmax increased 54%	200 mg BID	Not reported
Nevirapine

Subscribe to Nevirapine